Eli Lilly has announced that its daily weight loss pill orforglipron has cleared another late-stage trial, paving the way for potential approval from global regulators. The pill helped patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels, meeting its main goal in a study called ATTAIN-2.
According to the results, patients who took the highest dose of orforglipron lost an average of 10.5% of their weight over 72 weeks, compared to 2.2% for those taking a placebo. The treatment also improved key cardiovascular risk factors.
While some patients stopped taking the pill due to side effects, Eli Lilly’s chief scientific officer Daniel Skovronsky said that most patients stayed on the drug and that its “unprecedented efficacy” in treating obesity and Type 2 diabetes is a significant opportunity.
The company now has the full clinical trial data required to file for approvals of orforglipron globally. With more than 100 million adults in the US alone having obesity, an oral option like orforglipron could expand access to weight management treatments, especially if priced lower than current injections and receive broader insurance coverage.
Source: https://www.cnbc.com/2025/08/26/eli-lilly-weight-loss-pill-orforglipron-clears-trial-paving-way-for-approval.html